Agios Pharmaceuticals, Inc. stock is up 2.76% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 3 PUTs, 2 CALLs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|27 Oct 14:21||15 Dec, 2023||25.00||412|
|27 Oct 15:18||15 Dec, 2023||25.00||412|
|27 Oct 15:19||17 Nov, 2023||25.00||359|
|09 Nov 18:18||15 Dec, 2023||22.50||18|
|28 Nov 17:34||17 May, 2024||25.00||0|
Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.